60 DEGREES PHARMACEUTICALS, INC. 8-K

What Happened
60 Degrees Pharmaceuticals, Inc. (SXTP) filed an 8-K (Item 8.01) on June 3, 2026, disclosing that it intends to submit an application for a Commissioner’s National Priority Review Voucher if interim and/or final analyses of its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis support moving forward with a New Drug Application (NDA) submission to the FDA before the end of Q1 2028. The company provided this disclosure to inform investors of its current development and regulatory plans.

Key Details

• The disclosure was made in an Item 8.01 “Other Events” 8-K filed June 3, 2026.
• The trial in question is a randomized, placebo‑controlled study of tafenoquine in patients hospitalized with severe babesiosis.
• The company may apply for a Commissioner’s National Priority Review Voucher if trial results support an NDA submission to the FDA prior to the end of Q1 2028.
• The filing emphasizes these are forward‑looking statements subject to risks (clinical outcomes, regulatory interactions, market conditions) and refers investors to the company’s Risk Factors in its 10‑K and 10‑Q filings.

Why It Matters
A Commissioner’s National Priority Review Voucher, if granted, could enable an expedited FDA review pathway for an NDA and is therefore a meaningful regulatory milestone to monitor. For investors, the announcement signals management’s plan and timeline (targeting possible NDA activity before end of Q1 2028) but is conditional on positive trial results and regulatory processes. The 8-K stresses these plans are forward‑looking and not guaranteed, so outcomes (and any impact on the company’s outlook or valuation) depend on future clinical and regulatory developments.